
Soldano Ferrone

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8570171/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	Escape of Human Solid Tumors from T–Cell Recognition: Molecular Mechanisms and Functional Significance. Advances in Immunology, 1999, 74, 181-273.	1.1	998
2	Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. Cancer Discovery, 2017, 7, 1420-1435.	7.7	507
3	Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinial relevance. Trends in Immunology, 1995, 16, 487-494.	7.5	447
4	HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Trends in Molecular Medicine, 1999, 5, 178-186.	2.6	321
5	NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. Journal of Clinical Investigation, 2009, 119, 1251-1263.	3.9	313
6	Immunobiological Characterization of Cancer Stem Cells Isolated from Glioblastoma Patients. Clinical Cancer Research, 2010, 16, 800-813.	3.2	295
7	Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells. Cancer Cell, 2019, 35, 221-237.e8.	7.7	286
8	Tumor Antigen–Targeted, Monoclonal Antibody–Based Immunotherapy: Clinical Response, Cellular Immunity, and Immunoescape. Journal of Clinical Oncology, 2010, 28, 4390-4399.	0.8	285
9	Distribution and molecular characterization of a cell-surface and a cytoplasmic antigen detectable in human melanoma cells with monoclonal antibodies. International Journal of Cancer, 1981, 28, 293-300.	2.3	240
10	Down-Regulation of HLA Class I Antigen-Processing Molecules in Malignant Melanoma. American Journal of Pathology, 1999, 154, 745-754.	1.9	239
11	Defects in the Human Leukocyte Antigen Class I Antigen Processing Machinery in Head and Neck Squamous Cell Carcinoma: Association with Clinical Outcome. Clinical Cancer Research, 2005, 11, 2552-2560.	3.2	222
12	CTLA-4+ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis. Cancer Research, 2015, 75, 2200-2210.	0.4	217
13	Multiparametric plasma EV profiling facilitates diagnosis of pancreatic malignancy. Science Translational Medicine, 2017, 9, .	5.8	211
14	Immunoaffinityâ€based isolation of melanoma cellâ€derived exosomes from plasma of patients with melanoma. Journal of Extracellular Vesicles, 2018, 7, 1435138.	5.5	210
15	Immune Escape Associated with Functional Defects in Antigen-Processing Machinery in Head and Neck Cancer. Clinical Cancer Research, 2006, 12, 3890-3895.	3.2	200
16	Programmed Cell Death Ligand 1 Expression in Osteosarcoma. Cancer Immunology Research, 2014, 2, 690-698.	1.6	182
17	PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma. Clinical Cancer Research, 2016, 22, 470-478.	3.2	168
18	Human High Molecular Weight-Melanoma-Associated Antigen (HMW-MAA): A Melanoma Cell Surface Chondroitin Sulfate Proteoglycan (MSCP) with Biological and Clinical Significance. Critical Reviews in Immunology, 2004, 24, 267-296.	1.0	167

#	Article	IF	CITATIONS
19	HLA Class I Antigen Down-regulation in Primary Laryngeal Squamous Cell Carcinoma Lesions as a Poor Prognostic Marker. Cancer Research, 2006, 66, 9281-9289.	0.4	165
20	B7-H3: An Attractive Target for Antibody-based Immunotherapy. Clinical Cancer Research, 2021, 27, 1227-1235.	3.2	162
21	Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma. Cancer Immunology, Immunotherapy, 2008, 57, 197-206.	2.0	160
22	Soluble human leukocyte antigen-G serum level is elevated in melanoma patients and is further increased by interferon-? immunotherapy. Cancer, 2001, 92, 369-376.	2.0	155
23	β2-Microglobulin-Free HLA Class I Heavy Chain Epitope Mimicry by Monoclonal Antibody HC-10-Specific Peptide. Journal of Immunology, 2003, 171, 1918-1926.	0.4	150
24	Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. Cancer Immunology, Immunotherapy, 2009, 58, 1853-1862.	2.0	148
25	CSPG4 Protein as a New Target for the Antibody-Based Immunotherapy of Triple-Negative Breast Cancer. Journal of the National Cancer Institute, 2010, 102, 1496-1512.	3.0	148
26	Targeting ALDHbright Human Carcinoma–Initiating Cells with ALDH1A1-Specific CD8+ T Cells. Clinical Cancer Research, 2011, 17, 6174-6184.	3.2	148
27	CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma. Pigment Cell and Melanoma Research, 2011, 24, 1148-1157.	1.5	145
28	Genetic Evolution of T-cell Resistance in the Course of Melanoma Progression. Clinical Cancer Research, 2014, 20, 6593-6604.	3.2	145
29	Melanoma chondroitin sulfate proteoglycan enhances FAK and ERK activation by distinct mechanisms. Journal of Cell Biology, 2004, 165, 881-891.	2.3	133
30	Melanoma cell-derived exosomes in plasma of melanoma patients suppress functions of immune effector cells. Scientific Reports, 2020, 10, 92.	1.6	122
31	Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells. , 2014, 2, 25.		112
32	NK cells and T cells cooperate during the clinical course of colorectal cancer. OncoImmunology, 2014, 3, e952197.	2.1	110
33	Enrichment of CD56dimKIR+CD57+ highly cytotoxic NK cells in tumour-infiltrated lymph nodes of melanoma patients. Nature Communications, 2014, 5, 5639.	5.8	109
34	Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients. Clinical Cancer Research, 2016, 22, 5229-5237.	3.2	107
35	CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer. Clinical Cancer Research, 2017, 23, 707-716.	3.2	104
36	Down-regulation of HLA-A and HLA-Bw6, but not HLA-Bw4, allospecificities in leukemic cells: an escape mechanism from CTL and NK attack?. Blood, 2004, 103, 3122-3130.	0.6	102

#	Article	IF	CITATIONS
37	Classical and Nonclassical HLA Class I Antigen and NK Cell–Activating Ligand Changes in Malignant Cells: Current Challenges and Future Directions. Advances in Cancer Research, 2005, 93, 189-234.	1.9	102
38	Immune selective pressure and HLA class I antigen defects in malignant lesions. Cancer Immunology, Immunotherapy, 2006, 56, 227-236.	2.0	102
39	B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres. EBioMedicine, 2019, 47, 33-43.	2.7	101
40	HLA Class II Antigen Expression in Colorectal Carcinoma Tumors as a Favorable Prognostic Marker. Neoplasia, 2014, 16, 31-W15.	2.3	99
41	Epigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinoma. Scientific Reports, 2017, 7, 2290.	1.6	99
42	Selective Histocompatibility Leukocyte Antigen (Hla)-A2 Loss Caused by Aberrant Pre-mRNA Splicing in 624mel28 Melanoma Cells. Journal of Experimental Medicine, 1999, 190, 205-216.	4.2	98
43	Cancer-Initiating Cells from Colorectal Cancer Patients Escape from T Cell–Mediated Immunosurveillance In Vitro through Membrane-Bound IL-4. Journal of Immunology, 2014, 192, 523-532.	0.4	97
44	Immune Selection of Hot-Spot β2 <i>-Microglobulin</i> Gene Mutations, HLA-A2 Allospecificity Loss, and Antigen-Processing Machinery Component Down-Regulation in Melanoma Cells Derived from Recurrent Metastases following Immunotherapy. Journal of Immunology, 2005, 174, 1462-1471.	0.4	96
45	Constitutive and TNFα-inducible expression of chondroitin sulfate proteoglycan 4 in glioblastoma and neurospheres: Implications for CAR-T cell therapy. Science Translational Medicine, 2018, 10, .	5.8	96
46	HETEROGENEOUS DISTRIBUTION OF THE DETERMINANTS DEFINED BY MONOCLONAL ANTIBODIES ON HLA-A AND B ANTIGENS BEARING MOLECULES. Transplantation, 1982, 34, 18-23.	0.5	95
47	T Lymphocytes Redirected against the Chondroitin Sulfate Proteoglycan-4 Control the Growth of Multiple Solid Tumors both <i>In Vitro</i> and <i>In Vivo</i> . Clinical Cancer Research, 2014, 20, 962-971.	3.2	95
48	Mitochondrial miRNA Determines Chemoresistance by Reprogramming Metabolism and Regulating Mitochondrial Transcription. Cancer Research, 2019, 79, 1069-1084.	0.4	94
49	Expression and prognostic significance of prothymosin- \hat{l} ± and ERp57 in human gastric cancer. Surgery, 2007, 141, 41-50.	1.0	93
50	Functional and Clinical Relevance of Chondroitin Sulfate Proteoglycan 4. Advances in Cancer Research, 2010, 109, 73-121.	1.9	93
51	Multiple defects of the antigen-processing machinery components in human neuroblastoma: immunotherapeutic implications. Oncogene, 2005, 24, 4634-4644.	2.6	92
52	Blocking the formation of radiation-induced breast cancer stem cells. Oncotarget, 2014, 5, 3743-3755.	0.8	92
53	Cancer Immunotherapy Targeting the High Molecular Weight Melanoma-Associated Antigen Protein Results in a Broad Antitumor Response and Reduction of Pericytes in the Tumor Vasculature. Cancer Research, 2008, 68, 8066-8075.	0.4	91
54	Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells. Oncotarget, 2016, 7, 7390-7402.	0.8	89

#	Article	IF	CITATIONS
55	IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma. Clinical Cancer Research, 2020, 26, 5520-5533.	3.2	88
56	lpilimumab in the treatment of metastatic melanoma: management of adverse events. OncoTargets and Therapy, 2014, 7, 203.	1.0	87
57	Characterization of human lymphocyte antigen class I antigen-processing machinery defects in renal cell carcinoma lesions with special emphasis on transporter-associated with antigen-processing down-regulation. Clinical Cancer Research, 2003, 9, 1721-7.	3.2	87
58	The role of cancer stem cells in the modulation of anti-tumor immune responses. Seminars in Cancer Biology, 2018, 53, 189-200.	4.3	80
59	CAR T Cell-Based Immunotherapy for the Treatment of Glioblastoma. Frontiers in Neuroscience, 2021, 15, 662064.	1.4	80
60	CSPG4 as a Target of Antibody-Based Immunotherapy for Malignant Mesothelioma. Clinical Cancer Research, 2012, 18, 5352-5363.	3.2	78
61	Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer. Cancer Immunology, Immunotherapy, 2010, 59, 529-540.	2.0	77
62	Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy. Immunological Investigations, 2017, 46, 221-238.	1.0	77
63	TAP1 down-regulation in primary melanoma lesions: An independent marker of poor prognosis. International Journal of Cancer, 2001, 95, 23-28.	2.3	70
64	A High Molecular Weight Melanoma-Associated Antigen–Specific Chimeric Antigen Receptor Redirects Lymphocytes to Target Human Melanomas. Cancer Research, 2010, 70, 3027-3033.	0.4	70
65	SHP2 Is Overexpressed and Inhibits pSTAT1-Mediated APM Component Expression, T-cell Attracting Chemokine Secretion, and CTL Recognition in Head and Neck Cancer Cells. Clinical Cancer Research, 2013, 19, 798-808.	3.2	70
66	LOH in the HLA Class I Region at 6p21 Is Associated with Shorter Survival in Newly Diagnosed Adult Glioblastoma. Clinical Cancer Research, 2013, 19, 1816-1826.	3.2	70
67	Defective HLA class I antigen processing machinery in cancer. Cancer Immunology, Immunotherapy, 2018, 67, 999-1009.	2.0	68
68	Association of IFN-Î ³ Signal Transduction Defects with Impaired HLA Class I Antigen Processing in Melanoma Cell Lines. Clinical Cancer Research, 2011, 17, 2668-2678.	3.2	67
69	Structural polymorphism of human DR antigens. Nature, 1979, 279, 436-437.	13.7	66
70	Immunotherapy of Malignant Disease with Tumor Antigen–Specific Monoclonal Antibodies. Clinical Cancer Research, 2010, 16, 11-20.	3.2	65
71	STAT1-Induced HLA Class I Upregulation Enhances Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients. Cancer Immunology Research, 2015, 3, 936-945.	1.6	65
72	A review of B7-H3 and B7-H4 immune molecules and their role in ovarian cancer. Gynecologic Oncology, 2012, 127, 420-425.	0.6	64

#	Article	IF	CITATIONS
73	CSPG4-Specific Immunity and Survival Prolongation in Dogs with Oral Malignant Melanoma Immunized with Human CSPG4 DNA. Clinical Cancer Research, 2014, 20, 3753-3762.	3.2	64
74	HLA class II antigen-processing pathway in tumors: Molecular defects and clinical relevance. Oncolmmunology, 2017, 6, e1171447.	2.1	64
75	Association of tapasin and HLA class I antigen down-regulation in primary maxillary sinus squamous cell carcinoma lesions with reduced survival of patients. Clinical Cancer Research, 2003, 9, 4043-51.	3.2	63
76	Melanoma Cells Inhibit NK Cell Functions—Letter. Cancer Research, 2012, 72, 5428-5429.	0.4	61
77	Multiple Structural and Epigenetic Defects in the Human Leukocyte Antigen Class I Antigen Presentation Pathway in a Recurrent Metastatic Melanoma Following Immunotherapy. Journal of Biological Chemistry, 2015, 290, 26562-26575.	1.6	59
78	Immunological and clinical significance of HLA class I antigen processing machinery component defects in malignant cells. Oral Oncology, 2016, 58, 52-58.	0.8	58
79	Stimulation of human T lymphocytes by PHA-activated autologous T lymphocytes: Analysis of the role of la-like antigens with monoclonal antibodies. Immunogenetics, 1981, 12, 267-274.	1.2	57
80	A method to generate antigen-specific mAb capable of staining formalin-fixed, paraffin-embedded tissue sections. Journal of Immunological Methods, 2005, 299, 139-151.	0.6	56
81	Role of Tumor-Associated Macrophages in the Clinical Course of Pancreatic Neuroendocrine Tumors (PanNETs). Clinical Cancer Research, 2019, 25, 2644-2655.	3.2	56
82	Association of HL-A antigens and \hat{l}^2 2-microglobulin at the cellular and molecular level. Immunogenetics, 1975, 2, 183-197.	1.2	55
83	Functional Characterization of an scFv-Fc Antibody that Immunotherapeutically Targets the Common Cancer Cell Surface Proteoglycan CSPG4. Cancer Research, 2011, 71, 7410-7422.	0.4	54
84	Long Noncoding RNA MPRL Promotes Mitochondrial Fission and Cisplatin Chemosensitivity via Disruption of Pre-miRNA Processing. Clinical Cancer Research, 2019, 25, 3673-3688.	3.2	54
85	NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo. Cancers, 2020, 12, 2659.	1.7	54
86	B7-H3-targeted 212Pb radioimmunotherapy of ovarian cancer in preclinical models. Nuclear Medicine and Biology, 2017, 47, 23-30.	0.3	52
87	The SPPL3-Defined Glycosphingolipid Repertoire Orchestrates HLA Class I-Mediated Immune Responses. Immunity, 2021, 54, 132-150.e9.	6.6	52
88	Molecular and Functional Profiles of Exosomes From HPV(+) and HPV(â^') Head and Neck Cancer Cell Lines. Frontiers in Oncology, 2018, 8, 445.	1.3	50
89	Structural Relatedness of Distinct Determinants Recognized by Monoclonal Antibody TP25.99 on β2-Microglobulin-Associated and β2-Microglobulin-Free HLA Class I Heavy Chains. Journal of Immunology, 2000, 165, 3275-3283.	0.4	49
90	Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy. Journal of the National Cancer Institute, 2021, 113, 182-191.	3.0	49

#	Article	IF	CITATIONS
91	A novel chemoradiation targeting stem and nonstem pancreatic cancer cells by repurposing disulfiram. Cancer Letters, 2017, 409, 9-19.	3.2	48
92	Induction of immunogenic cell death in radiation-resistant breast cancer stem cells by repurposing anti-alcoholism drug disulfiram. Cell Communication and Signaling, 2020, 18, 36.	2.7	47
93	Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia. Clinical Cancer Research, 2021, 27, 3141-3153.	3.2	45
94	Lymphocytotoxic antibodies in systemic lupus erythematosus patients and their relatives. Arthritis and Rheumatism, 1980, 23, 265-272.	6.7	41
95	FCÎ ³ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical Relevance. Frontiers in Immunology, 2017, 8, 457.	2.2	41
96	Iron and Ferritin Modulate MHC Class I Expression and NK Cell Recognition. Frontiers in Immunology, 2019, 10, 224.	2.2	41
97	Distribution of antigenic determinants recognized by three monoclonal antibodies (Q2/70, Q5/6 and) Tj ETQq1 1	0,784314 1.2	l rgBT /Overlo
98	Monoclonal antibody-based immunotherapy of ovarian cancer: Targeting ovarian cancer cells with the B7-H3-specific mAb 376.96. Gynecologic Oncology, 2014, 132, 203-210.	0.6	40
99	212Pb-labeled B7-H3-targeting antibody for pancreatic cancer therapy in mouse models. Nuclear Medicine and Biology, 2018, 58, 67-73.	0.3	40
100	Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature. , 2018, 6, 126.		40
101	Targeting Radiation-Resistant Prostate Cancer Stem Cells by B7-H3 CAR T Cells. Molecular Cancer Therapeutics, 2021, 20, 577-588.	1.9	40
102	Down-regulation of Human Leukocyte Antigen class I heavy chain in tumors is associated with a poor prognosis in advanced esophageal cancer patients. International Journal of Oncology, 2012, 40, 965-974.	1.4	39
103	Proteomic profile of melanoma cellâ€derived small extracellular vesicles in patients' plasma: a potential correlate of melanoma progression. Journal of Extracellular Vesicles, 2021, 10, e12063.	5.5	38
104	Chondroitin sulfate proteoglycan-4: A biomarker and a potential immunotherapeutic target for canine malignant melanoma. Veterinary Journal, 2011, 190, e26-e30.	0.6	37
105	Decreased expression of mitochondrial miR-5787 contributes to chemoresistance by reprogramming glucose metabolism and inhibiting MT-CO3 translation. Theranostics, 2019, 9, 5739-5754.	4.6	36
106	Characterization of antigen processing machinery and Survivin expression in tonsillar squamous cell carcinoma. Cancer, 2003, 97, 2203-2211.	2.0	35
107	EGFR-mediated tumor immunoescape. Oncolmmunology, 2013, 2, e27215.	2.1	35
108	Antitumor Activity of BRAF Inhibitor and IFNα Combination in BRAF-Mutant Melanoma. Journal of the National Cancer Institute, 2016, 108, djv435.	3.0	35

#	Article	IF	CITATIONS
109	Anti-proliferative and pro-apoptotic activity of GD2 ganglioside-specific monoclonal antibody 3F8 in human melanoma cells. Oncolmmunology, 2015, 4, e1023975.	2.1	33
110	Monitoring native HLA-I trimer specific antibodies in Luminex multiplex single antigen bead assay: Evaluation of beadsets from different manufacturers. Journal of Immunological Methods, 2017, 450, 73-80.	0.6	33
111	HLA class I antigen processing machinery defects in antitumor immunity and immunotherapy. Trends in Cancer, 2021, 7, 1089-1101.	3.8	32
112	HLA class I downregulation is associated with enhanced NKâ€cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors. European Journal of Immunology, 2016, 46, 409-419.	1.6	31
113	212Pb-Labeled Antibody 225.28 Targeted to Chondroitin Sulfate Proteoglycan 4 for Triple-Negative Breast Cancer Therapy in Mouse Models. International Journal of Molecular Sciences, 2018, 19, 925.	1.8	31
114	The HDAC Inhibitor Domatinostat Promotes Cell-Cycle Arrest, Induces Apoptosis, and Increases Immunogenicity of Merkel Cell Carcinoma Cells. Journal of Investigative Dermatology, 2021, 141, 903-912.e4.	0.3	31
115	<i>In vitro</i> elimination of epidermal growth factor receptorâ€overexpressing cancer cells by CD32Aâ€chimeric receptor T cells in combination with cetuximab or panitumumab. International Journal of Cancer, 2020, 146, 236-247.	2.3	30
116	Differential clinical significance of αvl̃'3 expression in primary lesions of acral lentiginous melanoma and of other melanoma histotypes. , 2000, 89, 153-159.		28
117	α v β 3 expression on blood vessels and melanoma cells in primary lesions; differential association with tumor progression and clinical prognosis. Cancer Immunology, Immunotherapy, 2000, 49, 314-318.	2.0	28
118	CSPG4 as a prognostic biomarker in chordoma. Spine Journal, 2016, 16, 722-727.	0.6	28
119	Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapy. Journal of Clinical Investigation, 2020, 130, 4266-4281.	3.9	27
120	HLA Class I Antigen Processing Machinery Defects in Cancer Cells—Frequency, Functional Significance, and Clinical Relevance with Special Emphasis on Their Role in T Cell-Based Immunotherapy of Malignant Disease. Methods in Molecular Biology, 2020, 2055, 325-350.	0.4	26
121	Modifications to the Framework Regions Eliminate Chimeric Antigen Receptor Tonic Signaling. Cancer Immunology Research, 2021, 9, 441-453.	1.6	25
122	A Pan-Histone Deacetylase Inhibitor Enhances the Antitumor Activity of B7-H3–Specific CAR T Cells in Solid Tumors. Clinical Cancer Research, 2021, 27, 3757-3771.	3.2	25
123	Radiotherapy to Enhance Chimeric Antigen Receptor T-Cell Therapeutic Efficacy in Solid Tumors. JAMA Oncology, 2021, 7, 1051.	3.4	25
124	Phosphorylated Histone H3 (PHH3) Is a Superior Proliferation Marker for Prognosis of Pancreatic Neuroendocrine Tumors. Annals of Surgical Oncology, 2016, 23, 609-617.	0.7	24
125	CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes. Clinical Cancer Research, 2020, 26, 6321-6334.	3.2	24
126	Specific Lysis of Melanoma Cells by Receptor Grafted T Cells is Enhanced by Anti-Idiotypic Monoclonal Antibodies Directed to the scFv Domain of the Receptor. Journal of Investigative Dermatology, 1999, 112, 744-750.	0.3	23

#	Article	IF	CITATIONS
127	Expression status of folate receptor alpha is a predictor of survival in pancreatic ductal adenocarcinoma. Oncotarget, 2017, 8, 37646-37656.	0.8	23
128	Differential Immunogenicity of Two Peptides Isolated by High Molecular Weight-Melanoma-Associated Antigen-Specific Monoclonal Antibodies with Different Affinities. Journal of Immunology, 2005, 174, 7104-7110.	0.4	22
129	Intracellular antigens as targets for antibody based immunotherapy of malignant diseases. Molecular Oncology, 2015, 9, 1982-1993.	2.1	22
130	Chondroitin sulfate proteoglycan 4 as a target for chimeric antigen receptor-based T-cell immunotherapy of solid tumors. Expert Opinion on Therapeutic Targets, 2015, 19, 1339-1350.	1.5	22
131	Human Leukocyte Antigen Class I Antigen-Processing Machinery Upregulation by Anticancer Therapies in the Era of Checkpoint Inhibitors. JAMA Oncology, 2022, 8, 462.	3.4	22
132	Human High Molecular Weight Melanoma-Associated Antigen Mimicry by Mouse Anti-Idiotypic Monoclonal Antibody MK2-23: Enhancement of Immunogenicity of Anti-Idiotypic Monoclonal Antibody MK2-23 by Fusion with Interleukin 2. Cancer Research, 2005, 65, 6976-6983.	0.4	21
133	Human preprocalcitonin self-antigen generates TAP-dependent and -independent epitopes triggering optimised T-cell responses toward immune-escaped tumours. Nature Communications, 2018, 9, 5097.	5.8	21
134	lncRNA CISAL Inhibits BRCA1 Transcription by Forming a Tertiary Structure at Its Promoter. IScience, 2020, 23, 100835.	1.9	21
135	Radioimmunodetection of Melanoma: Preliminary Results of a Prospective Study. International Journal of Biological Markers, 1986, 1, 47-54.	0.7	20
136	Computationally Guided Design of Single-Chain Variable Fragment Improves Specificity of Chimeric Antigen Receptors. Molecular Therapy - Oncolytics, 2019, 15, 30-37.	2.0	20
137	Identification of CSPG4 as a promising target for translational combinatorial approaches in osteosarcoma. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591985549.	1.4	20
138	Disulfiram Acts as a Potent Radio-Chemo Sensitizer in Head and Neck Squamous Cell Carcinoma Cell Lines and Transplanted Xenografts. Cells, 2021, 10, 517.	1.8	20
139	High IDO1 Expression Is Associated with Poor Outcome in Patients with Anal Cancer Treated with Definitive Chemoradiotherapy. Oncologist, 2019, 24, e275-e283.	1.9	18
140	ADAM12-L confers acquired 5-fluorouracil resistance in breast cancer cells. Scientific Reports, 2017, 7, 9687.	1.6	17
141	Spatial Analysis and Clinical Significance of HLA Class-I and Class-II Subunit Expression in Non–Small Cell Lung Cancer. Clinical Cancer Research, 2021, 27, 2837-2847.	3.2	17
142	Mitochondrial fission induces immunoescape in solid tumors through decreasing MHC-I surface expression. Nature Communications, 2022, 13, .	5.8	17
143	Analysis of the NIH Workshop Monoclonal Antibodies to Human Melanoma Antigens. Hybridoma, 1982, 1, 473-482.	0.9	16
144	B7-H3 targeted antibody-based immunotherapy of malignant diseases. Expert Opinion on Biological Therapy, 2021, 21, 587-602.	1.4	16

#	Article	IF	CITATIONS
145	Detection of Chondroitin Sulfate Proteoglycan 4 (CSPG4) in Melanoma. Methods in Molecular Biology, 2014, 1102, 523-535.	0.4	16
146	CD16â€158â€valine chimeric receptor T cells overcome the resistance of KRASâ€mutated colorectal carcinoma cells to cetuximab. International Journal of Cancer, 2020, 146, 2531-2538.	2.3	15
147	Overexpression of miR-489 enhances efficacy of 5-fluorouracil-based treatment in breast cancer stem cells by targeting XIAP. Oncotarget, 2017, 8, 113837-113846.	0.8	15
148	Enhancement of anti-leukemia activity of NK cells <i>in vitro</i> and <i>in vivo</i> by inhibition of leukemia cell-induced NK cell damage. Oncotarget, 2016, 7, 2070-2079.	0.8	15
149	Distribution of a Cross-Species Melanoma-Associated Antigen in Normal and Neoplastic Human Tissues. Journal of Investigative Dermatology, 1985, 85, 340-346.	0.3	14
150	Rabbit Complement in the Lymphocytotoxicity Test. Tissue Antigens, 1977, 9, 223-226.	1.0	14
151	Dendritic cell maturation in HCV infection: Altered regulation of MHC class I antigen processing-presenting machinery. Journal of Hepatology, 2014, 61, 242-251.	1.8	14
152	Improving the Clinical Significance of Preclinical Immunotherapy Studies through Incorporating Tumor Microenvironment–like Conditions. Clinical Cancer Research, 2020, 26, 4448-4453.	3.2	14
153	Significance of the intraindividual variability of HLA IgG antibodies in renal disease patients observed with different beadsets monitored with two different secondary antibodies on a Luminex platform. Immunologic Research, 2018, 66, 584-604.	1.3	13
154	Methods for improving the immunogenicity and efficacy of cancer vaccines. Expert Opinion on Biological Therapy, 2018, 18, 765-784.	1.4	13
155	Hidden Immunotherapy Targets Challenge Dogma. Science Translational Medicine, 2011, 3, 99ps38.	5.8	12
156	Effect of p53 activity on the sensitivity of human glioblastoma cells to PARPâ€1 inhibitor in combination with topoisomerase i inhibitor or radiation. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2014, 85, 953-961.	1.1	12
157	Peritumoral Immune Infiltrate as a Prognostic Biomarker in Thin Melanoma. Frontiers in Immunology, 2020, 11, 561390.	2.2	12
158	Role of the anatomic site in the association of HLA class I antigen expression level in metastases with clinical response to ipilimumab therapy in patients with melanoma. , 2020, 8, e000209.		12
159	Human Hepatitis B Virus Negatively Impacts the Protective Immune Crosstalk Between Natural Killer and Dendritic Cells. Hepatology, 2021, 74, 550-565.	3.6	12
160	Defective HLA Class I Expression and Patterns of Lymphocyte Infiltration in Chordoma Tumors. Clinical Orthopaedics and Related Research, 2021, 479, 1373-1382.	0.7	11
161	Novel Tumor Antigen-Specific Monoclonal Antibody-Based Immunotherapy to Eradicate Both Differentiated Cancer Cells and Cancer-Initiating Cells in Solid Tumors. Seminars in Oncology, 2014, 41, 685-699.	0.8	10
162	Translational Research in Cutaneous Melanoma: New Therapeutic Perspectives. Anti-Cancer Agents in Medicinal Chemistry, 2018, 18, 166-181.	0.9	10

#	Article	IF	CITATIONS
163	Immune checkpoint inhibitors for the treatment of melanoma. Expert Opinion on Biological Therapy, 2022, 22, 563-576.	1.4	10
164	Cancer Stem Cells Are Possible Key Players in Regulating Anti-Tumor Immune Responses: The Role of Immunomodulating Molecules and MicroRNAs. Cancers, 2021, 13, 1674.	1.7	9
165	Differential role of HLA-A and HLA-B, C expression levels as prognostic markers in colon and rectal cancer. , 2022, 10, e004115.		9
166	AIRE polymorphism, melanoma antigen-specific T cell immunity, and susceptibility to melanoma. Oncotarget, 2016, 7, 60872-60884.	0.8	8
167	A fast, simple, and cost-effective method of expanding patient-derived xenograft mouse models of pancreatic ductal adenocarcinoma. Journal of Translational Medicine, 2020, 18, 255.	1.8	8
168	Chondroitin Sulfate Proteoglycan-4 (CSPG4)-Specific Monoclonal Antibody 225.28 in Detection of Acute Myeloid Leukemia Blasts. Oncology Research, 2015, 22, 117-121.	0.6	7
169	HLA class I antigen processing machinery (APM) component expression and PD-1:PD-L1 pathway activation in HIV-infected head and neck cancers. Oral Oncology, 2018, 77, 92-97.	0.8	7
170	Novel <i>ANO5</i> mutation c.1067G>T (p.C356F) identified by whole genome sequencing in a big family with atypical gnathodiaphyseal dysplasia. Head and Neck, 2019, 41, 230-238.	0.9	7
171	Antigen mimicry as an effective strategy to induce CSPG4-targeted immunity in dogs with oral melanoma: a veterinary trial. , 2022, 10, e004007.		7
172	Cancer Stem Cells: The Players of Immune Evasion from Immunotherapy. Resistance To Targeted Anti-cancer Therapeutics, 2019, , 223-249.	0.1	6
173	A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation. Journal of Translational Medicine, 2021, 19, 17.	1.8	6
174	Pre-Clinical Evaluation of B7-H3-Specific Chimeric Antigen Receptor T-Cells for the Treatment of Acute Myeloid Leukemia. Blood, 2018, 132, 701-701.	0.6	6
175	A fresh look at an old story: revisiting HLA class II antigen expression by melanoma cells. Expert Review of Dermatology, 2006, 1, 805-823.	0.3	5
176	Emerging BRAF inhibitors for melanoma. Expert Opinion on Emerging Drugs, 2013, 18, 431-443.	1.0	5
177	Melanoma initiating cells: where do we stand?. Melanoma Management, 2015, 2, 109-114.	0.1	5
178	High Antigen Processing Machinery component expression in Langerhans cells from melanoma patients' sentinel lymph nodes. Cellular Immunology, 2017, 320, 29-37.	1.4	5
179	Potential Role of HLA Class I Antigens in the Glycolytic Metabolism and Motility of Melanoma Cells. Cancers, 2019, 11, 1249.	1.7	5
180	IL-15/B7-H3 TriKEs-Based Immunotherapy for Pancreatic Ductal Adenocarcinoma. Journal of the American College of Surgeons, 2019, 229, S176.	0.2	5

#	Article	IF	CITATIONS
181	Perspectives in melanoma: meeting report from the "Melanoma Bridge―(December 5th–7th, 2019,) Tj ETC	2q1 _{.8} 1 0.78	34314 rgBT
182	B7-H3-targeted Radioimmunotherapy of Human Cancer. Current Medicinal Chemistry, 2020, 27, 4016-4038.	1.2	5
183	HLA Class I Downregulation in Progressing Metastases of Melanoma Patients Treated With Ipilimumab. Pathology and Oncology Research, 2022, 28, 1610297.	0.9	5
184	Tumor Antigen-Specific Monoclonal Antibody-Based Immunotherapy, Cancer Initiating Cells and Disease Recurrence. Resistance To Targeted Anti-cancer Therapeutics, 2013, , 25-47.	0.1	4
185	Canine Melanoma Immunology and Immunotherapy: Relevance of Translational Research. Frontiers in Veterinary Science, 2022, 9, 803093.	0.9	4
186	Sera from Volunteers Immunized by Planned Blood Transfusions as a Source of Dr Cytotoxic Typing Reagents. Immunological Investigations, 1979, 8, 93-106.	0.9	3
187	Therapeutic Monoclonal Antibodies: Introduction. Seminars in Oncology, 2014, 41, 556-558.	0.8	3
188	The Humoral Theory of Transplantation. Journal of Immunology Research, 2017, 2017, 1-3.	0.9	3
189	High TIL, HLA, and Immune Checkpoint Expression in Conventional High-Grade and Dedifferentiated Chondrosarcoma and Poor Clinical Course of the Disease. Frontiers in Oncology, 2021, 11, 598001.	1.3	3
190	A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation. Journal of Experimental and Clinical Cancer Research, 2021, 40, 240.	3.5	3
191	Multidisciplinary Approach to Patient with Malignant Melanoma. Anti-Cancer Agents in Medicinal Chemistry, 2013, 13, 887-900.	0.9	3
192	Risk Prediction Model for Cisplatin-Associated Acute Kidney Injury. Journal of Clinical Oncology, 2018, 36, 2453-2454.	0.8	2
193	Variability in immune infiltrates and HLA expression in cholangiocarcinoma Journal of Clinical Oncology, 2014, 32, 230-230.	0.8	2
194	Activation of the complement system by H-2 alloantisera: Differential susceptibility to lysis of thymocytes and lymphocytes. Immunogenetics, 1975, 2, 199-203.	1.2	1
195	The Major Portion of Rabbit Antibody to Serum HLAâ€A9 Antigens is Directed to Allospecificity. Tissue Antigens, 1978, 12, 153-155.	1.0	1
196	Changes in Serum Ganglioside and Antibody Levels in Soft Tissue Sarcoma. Cancer Journal (Sudbury,) Tj ETQq0 0	0 IgBT /O	verlock 10 T
197	The Effects of Anti-High Molecular Weight-Melanoma Associated Antigen (HMW-MAA) Monoclonal Antibodies (mAb) Against 11q23 Positive Acute Leukemia Cells Blood, 2006, 108, 4550-4550.	0.6	1
198	Expression and clinical significance of antigen presentation components beta-2 microglobulin, HLA class I heavy chains, and HLA class II in non-small cell lung cancer (NSCLC) Journal of Clinical Oncology, 2018, 36, 12015-12015.	0.8	1

#	Article	IF	CITATIONS
199	Anti-inflammatory biologic therapies and immune surveillance of melanoma. Expert Review of Dermatology, 2008, 3, 129-131.	0.3	0
200	Response to the letter to the editors by Ottaiano et al.: "Cetuximab-dependent ADCC in cancer: dream or reality?― Cancer Immunology, Immunotherapy, 2010, 59, 1609-1610.	2.0	0
201	The Antileukemic Effect of NK and NK-T Cells Against Chronic Myelogenous Leukemia Is Dominated by Interactions between Activating Molecules and Their Ligands Which Overcome Inhibitory KIR-MHC Class I Interaction Blood, 2004, 104, 2948-2948.	0.6	0
202	Dose-seeking and efficacy study of combination BRAFi and high-dose IFN (HDI) for therapy of advanced melanoma Journal of Clinical Oncology, 2014, 32, TPS9110-TPS9110.	0.8	0
203	Phase I-II study of the combination vemurafenib plus peg-interferon in advanced melanoma patients harboring the V600BRAF mutation Journal of Clinical Oncology, 2014, 32, TPS9105-TPS9105.	0.8	0
204	Intact APM and PD-1:PD-L1 pathway upregulation in HIV-infected head and neck cancer patients Journal of Clinical Oncology, 2017, 35, 6058-6058.	0.8	0
205	Diversity of Extracellular Vesicles (EV) in Plasma of Cancer Patients. Physiology, 0, , .	4.0	0
206	Abstract 2812: CSPG4-specific CAR.CIK lymphocyte-based immunotherapy to eliminate HLA class I-defective melanoma tumors. Cancer Research, 2022, 82, 2812-2812.	0.4	0